Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cytarabine

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
    • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.

    The EU Clinical Trials Register currently displays   33594   clinical trials with a EudraCT protocol, of which   5439   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    140 result(s) found for: Cytarabine . Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2015-004896-60 Sponsor Protocol Number: LUMC2015-02 Start Date*: 2015-11-26
    Sponsor Name:Leiden University Medical Center
    Full Title: Decitabine-cytarabine chemotherapy in elderly AML and high risk MDS patients (> 65 years) with high early mortality risk
    Medical condition: Acute myeloid leukemia and high risk myelodysplasia
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000344-42 Sponsor Protocol Number: AG-221-AML-004 Start Date*: 2016-01-21
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemi...
    Medical condition: Treatment of subjects 60 years or older with acute myeloid leukemia (AML) refractory to or relapsed after second- or third-line AML therapy and positive for an isocitrate dehydrogenase 2 (IDH2) mut...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10060558 Acute myeloid leukemia recurrent LLT
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) GB (Ongoing) ES (Ongoing) DK (Ongoing) BE (Ongoing) AT (Ongoing) CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001233-89 Sponsor Protocol Number: SGI-110-04 Start Date*: 2015-05-15
    Sponsor Name:Astex Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for I...
    Medical condition: Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) SE (Ongoing) BE (Ongoing) HU (Ongoing) DE (Ongoing) GB (Ongoing) NL (Ongoing) FI (Ongoing) CZ (Completed) AT (Ongoing) ES (Ongoing) PL (Ongoing) FR (Ongoing) DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003065-15 Sponsor Protocol Number: WO29519 Start Date*: 2015-12-15
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE III STUDY OF IDASANUTLIN, AN MDM2 ANTAGONIST, WITH CYTARABINE VERSUS CYTARABINE PLUS PLACEBO IN PATIENTS WITH RELAPSED OR REFRACTO...
    Medical condition: Relapsed or refractory acute myeloid leukemia (AML).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) FI (Ongoing) GB (Ongoing) NO (Ongoing) BE (Ongoing) NL (Ongoing) ES (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002345-39 Sponsor Protocol Number: Göteborg University Start Date*: 2006-02-16
    Sponsor Name:NOPHO NHL-group
    Full Title: B-NHL BFM 04
    Medical condition: B-cell lymphoma or B-ALL in children up to 18 years of age
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000319-15 Sponsor Protocol Number: FLUGAZA Start Date*: 2014-07-25
    Sponsor Name:Fundación PETHEMA
    Full Title: A phase III, multicentre, randomized, open label clinical trial comparing azacytidine (Vidaza®) versus fludarabine plus cytarabine in elderly patients with newly diagnosed acute myeloid leukemia.
    Medical condition: Newly diagnosed acute myeloid leukemia.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001086-41 Sponsor Protocol Number: UKM10_0014 Start Date*: 2012-02-28
    Sponsor Name:University Hospital of Muenster
    Full Title: A randomized, placebo-controlled, multi-center phase I/II trial to assess the safety and efficacy of nintedanib (BIBF 1120) added to low-dose cytarabine in elderly patients with AML unfit for an in...
    Medical condition: untreated acute myeloid leukemia patients unfit for an intensive treatment
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005794-29 Sponsor Protocol Number: GFM-BAR-C-2005 Start Date*: 2006-03-30
    Sponsor Name:Groupe français des Myélodysplasies
    Full Title: Traitement des syndromes myélodysplasiques par l'association aracytine et bortezomib
    Medical condition: Myelodysplastic syndrome (MDS) is a clonal disease of the bone marrow stem cells. The disease is frequently associated with cytopenia and/or blastosis. An evolution to an acute leukemia is not unfr...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002822-19 Sponsor Protocol Number: B1371019 Start Date*: 2018-07-09
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN ...
    Medical condition: ACUTE MYELOID LEUKEMIA
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) CZ (Ongoing) SE (Ongoing) HU (Ongoing) PL (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023691-33 Sponsor Protocol Number: MUV-MEMMAT-01 Start Date*: 2011-05-05
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Kinder- und Jugendheilkunde
    Full Title: A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma
    Medical condition: Recurrent/progressive medulloblastoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Ongoing) SE (Restarted) CZ (Ongoing) DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001891-13 Sponsor Protocol Number: LeMLAR Start Date*: 2012-12-17
    Sponsor Name:University Hospital Essen
    Full Title: Lenalidomide in conjunction with methotrexate, leucovorin, cytarabine and rituximab for the treatment of relapsed or refractory CD20-positive aggressive lymphomas: an open-label, multicenter phase ...
    Medical condition: Relapsed or refractory CD20-positive aggressive B-cell lymphomas
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003031-19 Sponsor Protocol Number: IELSG42 Start Date*: 2014-12-15
    Sponsor Name:IELSG (INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP)
    Full Title: An international phase II trial assessing tolerability and efficacy of sequential Methotrexate-Aracytin-based combination and R-ICE combination, followed by high-dose chemotherapy supported by auto...
    Medical condition: systemic diffuse large B-cell lymphoma with central nervous system involvement at diagnosis or relapse
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000699-24 Sponsor Protocol Number: PHRC2010-03 Start Date*: 2014-10-02
    Sponsor Name:CHU Angers-DAMR
    Full Title: Essai de phase 3 visant à améliorer la survie globale des LAM de l’adulte de 18 à 60 ans en comparant l’idarubicine à forte dose à la daunorubicine à l’induction, la cytarabine à haute-dose et à do...
    Medical condition: Leucémie aiguë myéloïde
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003081-18 Sponsor Protocol Number: BRD/07/137 Start Date*: 2008-09-29
    Sponsor Name:University College Hospital
    Full Title: Phase II study of low intensity allogeneic transplantation in Mantle Cell Lymphoma
    Medical condition: Mantle Cell Lymphoma (MCL) is an increasingly recognised yet rare sub-type of non-hodgkin's Lymphoma (NHL), representing between 5 and 8% of all cases. Typically a disease of the elderly with a me...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014462-26 Sponsor Protocol Number: DB-AML-01 Start Date*: 2010-05-04
    Sponsor Name:Ghent University Hospital
    Full Title: Dutch-Belgian pediatric AML protocol for children with newly diagnosed acute myeloid leukemia, based on the NOPHO-AML 2004 study
    Medical condition: Acute Myeloid Leukemia in children
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004321-95 Sponsor Protocol Number: AMLSG 07-04 Start Date*: 2005-05-26
    Sponsor Name:University of Ulm
    Full Title: RANDOMIZED PHASE II-STUDY ON VALPROIC ACID, ALL-TRANS RETINOIC ACID AND THEIR COMBINATION IN INDUCTION AND CONSOLIDATION THERAPY AS WELL AS PEGFILGRASTIM AFTER CONSOLIDATION THERAPY IN YOUNGER PATI...
    Medical condition: newly diagnosed acute myeloid leukemia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002823-15 Sponsor Protocol Number: 1968 Start Date*: 2005-10-25
    Sponsor Name:Nottingham University Hospitals NHS Trust
    Full Title: A PHASE I/II TRIAL OF THE USE OF SIROLIMUS (RAPAMUNE) AND LOW DOSE ARA-C IN OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA (AML)
    Medical condition: Acute myeloid leukaemia (AML) and high risk myelodysplasia (MDS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-002610-23 Sponsor Protocol Number: M14-387 Start Date*: 2015-02-24
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 1/2 Study of Venetoclax in Combination with Low-Dose Cytarabine in Treatment-Naïve Subjects with Acute Myelogenous Leukemia Who Are ≥ 60 Years of Age and Who Are Not Eligible for Standard A...
    Medical condition: Acute Myelogenous Leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10001941 AML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004890-28 Sponsor Protocol Number: AC220-007 Start Date*: 2014-06-18
    Sponsor Name:Daiichi Sankyo Inc
    Full Title: A Phase 3 Open-Label Randomized Study of Quizartinib Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-li...
    Medical condition: Refractory or Relapsed FLT3-ITD Positive Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Ongoing) DE (Ongoing) IT (Ongoing) NL (Ongoing) ES (Ongoing) BE (Ongoing) HU (Ongoing) CZ (Ongoing) HR (Ongoing) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000140-42 Sponsor Protocol Number: 2215-CL-0301 Start Date*: 2016-04-20
    Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)
    Full Title: A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
    Medical condition: Relapsed or Refractory Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) GB (Ongoing) BE (Ongoing) ES (Ongoing) IE (Ongoing) FR (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-Sun Nov 18 15:03:38 GMT 2018 | 30 Churchill Place, Canary Wharf, London E14 5EU     Legal notice
    EMA HMA